olivLaw · European equity research
Abivax ABVX.PA
France · Euronext Paris · ISIN FR0012333284 · Vertical: Listed companies from France
At the close of 05 Nov 2026, Abivax (ABVX.PA) stock was 77.65 EUR (−2.39% on the day), with market capitalisation 5.4 bn EUR, dividend yield 0.00%, beta 1.95, 52-week range 63.10–135.00 EUR.
Data as of · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 42.4
- weak (30–45)
- Bollinger (20, 2)
- 75.52 – 83.63
- in the lower half of the band · %B 0.26 · band width 10.2%
- SMA 50 / 200
- 86.26 / 98.48
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -2.01 / -2.36
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | −3.5% | +0.4% | −3.9 pp | — |
| 3 months | −29.5% | −3.3% | −26.3 pp | — |
| 6 months | −27.9% | +4.0% | −31.9 pp | — |
| Year to date | −35.5% | +8.1% | −43.6 pp | — |
| 1 year | −8.8% | +10.7% | −19.5 pp | −8.8% |
| 3 years | +730.5% | +50.1% | +680.4 pp | −10.0% |
| 5 years | +180.3% | +43.6% | +136.7 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | unavailable | unavailable | unavailable | unavailable |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable |
| Net income | -60.7 m | -147.7 m | -176.2 m | -336.1 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -3.18 | -3.43 | -2.80 | -4.83 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | unavailable | unavailable |
| Free cash flow | -54.2 m | -97.4 m | -154.7 m | -161.3 m |
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 516.7 m EUR
- Financial debt
- unavailable EUR
- Net debt
- unavailable EUR
- Equity
- 455.2 m EUR
- Total assets
- 584.3 m EUR
- Debt / equity
- unavailable
- Current ratio
- 8.75x
- ROE
- -135.6%
- ROA
- -85.1%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (EUR)
Income statement · EUR
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Research & development | 48.3 m | 103.2 m | 146.5 m | 177.8 m | esef· 07 Apr 2026verified |
| Operating income | -64.8 m | -127.4 m | -173.0 m | -246.1 m | esef· 07 Apr 2026verified |
| Interest expense | 7.0 m | 27.9 m | 17.0 m | 111.7 m | esef· 07 Apr 2026verified |
| Pre-tax income | -60.7 m | -147.7 m | -176.2 m | -330.3 m | esef· 07 Apr 2026verified |
| Income tax | 0 | 0 | 0 | 5.8 m | esef· 07 Apr 2026verified |
| Net income | -60.7 m | -147.7 m | -176.2 m | -336.1 m | esef· 07 Apr 2026verified |
| Diluted EPS | -3.18 | -3.43 | -2.80 | -4.83 | esef· 07 Apr 2026verified |
| Weighted average diluted shares | 19.1 m | 43.1 m | 63.0 m | 69.5 m | esef· 07 Apr 2026verified |
| Dividend per share | 0.00 | 0.00 | 0.00 | 0.00 | esef· 07 Apr 2026verified |
Balance sheet · EUR
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Cash | 27.0 m | 251.9 m | 144.2 m | 516.7 m | esef· 07 Apr 2026verified |
| Current assets | 36.2 m | 286.0 m | 170.7 m | 551.2 m | esef· 07 Apr 2026verified |
| Goodwill | 18.4 m | 18.4 m | 18.4 m | 18.4 m | esef· 07 Apr 2026verified |
| Intangibles (excl. goodwill) | 6.6 m | 6.6 m | 6.6 m | 6.6 m | esef· 07 Apr 2026verified |
| Total assets | 75.5 m | 327.1 m | 205.2 m | 584.3 m | esef· 07 Apr 2026verified |
| Current liabilities | 51.5 m | 90.7 m | 94.0 m | 63.0 m | esef· 07 Apr 2026verified |
| Equity | 7.2 m | 196.0 m | 40.6 m | 455.2 m | esef· 07 Apr 2026verified |
| Shares outstanding at year end | 19.1 m | 43.1 m | 62.9 m | 69.6 m | esef· 07 Apr 2026derived |
Cash flow · EUR
| Line | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|
| Operating cash flow | -53.9 m | -97.1 m | -154.1 m | -161.1 m | esef· 07 Apr 2026verified |
| Capex | 288.0 k | 265.0 k | 640.0 k | 142.0 k | esef· 07 Apr 2026verified |
| Free cash flow | -54.2 m ≈ | -97.4 m ≈ | -154.7 m ≈ | -161.3 m ≈ | esef· 07 Apr 2026derived |
| Investing cash flow | -12.0 m | -8.1 m | 15.8 m | -8.2 m | esef· 07 Apr 2026verified |
| Financing cash flow | 32.2 m | 335.3 m | 28.2 m | 547.3 m | esef· 07 Apr 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 3 of at least 6
- score weight coverage: 18.8% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 5.4 bn EUR
Key indicators
Coverage and freshness
Score by group
19% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the base of the ratio is not positive
no valuation method could be computed
Assumptions (illustrative, editorial)
- Risk-free rate
- 3.0%
- Equity risk premium
- 5.5%
- Beta (default)
- 1.00
- Cost of equity
- 8.5%
- Terminal growth
- 2.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -2.2x | 0 (on a fixed band) | 33% |
| Current ratio · Balance sheet | 8.7x | 100 (on a fixed band) | 22% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -3.0% | 0 (on a fixed band) | 44% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
ABIVAX (ABVX.PA). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: ROE -135.6%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 8.7x
What contradicts it
- Interest coverage: -2.2x
- FCF yield: -3.0%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Listed companies from France · same country · compared with 40 companies
Multiples and returns vs the median
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AI.PAL'air Liquide Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude | 109.3 bn | 33.2 | 12.9% | 12.2% | −2.0% | +26% / +32% |
| BN.PADanone | 44.1 bn | 21.9 | 11.9% | 7.4% | −0.9% | −11% / +16% |
| AC.PAAccor | 13.8 bn | 30.7 | 9.6% | 8.0% | +0.6% | +6% / +56% |
| ADP.PAAeroports De Paris | 11.7 bn | 34.1 | 7.8% | 5.6% | +12.1% | −7% / +4% |
| AKE.PAArkema | 7.1 bn | 115.4 | 0.9% | 0.7% | −5.0% | +12% / −37% |
| ALO.PAAlstom | 5.8 bn | 18.3 | 3.1% | 1.7% | +3.7% | −51% / −4% |
| AF.PAAir France - Klm | 4.3 bn | 13.6 | — | 1.0% | +4.8% | +20% / +9% |
| ATE.PAAlten | 3.1 bn | 29.5 | 4.8% | 2.6% | −1.1% | +33% / −29% |
| BB.PASociete Bic | 2.7 bn | 31.3 | 5.0% | 4.1% | −4.8% | +32% / +5% |
| ANTIN.PAAntin Infrastructure Partners | 1.4 bn | 13.0 | 21.9% | 36.6% | −8.1% | −24% / −35% |
| 74SW.PA74software | 792.7 m | 20.9 | 8.9% | 8.5% | +44.8% | −13% / +41% |
| AUB.PAAubay | 667.4 m | 17.8 | 13.6% | 6.3% | +11.3% | +3% / +45% |
| ASY.PAAssystem | 507.1 m | 69.9 | 2.5% | 1.1% | +7.4% | −19% / −18% |
| ATO.PAAtos Se | 483.0 m | — | -23,400.0% | -17.5% | −16.5% | −45% / −94% |
| ARAMI.PAAramis Group | 298.8 m | 15.0 | 10.0% | 0.8% | +6.3% | −33% / −16% |
| ARVEN.PAArverne Group | 246.1 m | — | -14.0% | -115.3% | +27.0% | +20% / −35% |
| BGO.PACompagnie Chargeurs Invest | 189.4 m | — | -8.6% | -5.7% | −2.9% | unavailable / unavailable |
| ALCIS.PACatering International & Services | 145.0 m | 28.4 | 9.3% | 1.9% | +5.8% | +39% / +107% |
| ALCGM.PACegedim | 144.6 m | — | -2.6% | -1.2% | +10.9% | −26% / −49% |
| ATEME.PAAteme | 144.0 m | 151.3 | 2.8% | 1.0% | +2.2% | +82% / +77% |
| ALHEX.PAHexaom | 144.0 m | 6.7 | 9.9% | 2.2% | +13.1% | −32% / +7% |
| ALBON.PACompagnie Lebon | 111.7 m | 16.5 | 4.2% | 8.8% | −17.9% | +6% / +8% |
| ALHYF.PALhyfe | 75.8 m | — | -33.4% | -570.5% | +287.2% | unavailable / unavailable |
| ALFER.PASergeferrari Group | 61.5 m | 11.5 | 5.1% | 1.5% | +7.4% | −33% / −27% |
| ABEO.PAAbeo | 60.8 m | 7.3 | 6.9% | 3.0% | +12.6% | −13% / −54% |
1- and 3-year price returns: for ABVX.PA from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
The qualitative analysis has not been written for this company yet.
Products, market & competition
The qualitative analysis has not been written for this company yet.
News & filings
In the press
- Abivax ( NASDAQ : ABVX ) Stock Price Target Lowered at WedbushSurge — GDELT DOC · 21 Oct 2026 · RO
- Wedbush Issues Pessimistic Forecast for Abivax ( NASDAQ : ABVX ) Stock PriceSurge — GDELT DOC · 21 Oct 2026 · RO
- STAT+: Abivax has still not been acquired. What’s going on?STAT News · 03 Sept 2026 · EN
- Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBCCNBC World · 10 Jul 2026 · EN
- Biotech takeover target Abivax sinks over 30% after bowel disease drug trial updateCNBC World · 02 Jun 2026 · EN
Annual reports (ESEF)
- Annual report 202507 Apr 2026
- Annual report 202415 Apr 2025
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.